Santhera Pharmaceuticals Holding (CH:SANN)
:SANN
Want to see CH:SANN full AI Analyst Report?
SANN Stock Chart & Stats
CHF17.62
-CHF0.14(-0.88%)
At close: 4:00 PM EST
CHF17.62
-CHF0.14(-0.88%)
Day’s Range― - ―
52-Week RangeCHF9.38 - CHF18.84
Previous CloseN/A
Volume24.19K
Average Volume (3M)55.85K
Market Cap
CHF235.17M
Enterprise ValueCHF312.10M
Total Cash (Recent Filing)CHF22.44M
Total Debt (Recent Filing)CHF97.77M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Sep 21, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding15,456,525
10 Day Avg. Volume57,231
30 Day Avg. Volume55,851
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)-13.88
Price to Sales (P/S)2.12
P/FCF Ratio-4.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF30.00Price Target Upside70.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.6
Revenue Forecast (FY)CHF96.35M
Bulls Say, Bears Say
Bulls Say
Rare-disease Specialty FocusSanthera’s specialization in rare neuromuscular diseases and ownership of an approved core product (AGAMREE) supports durable demand, higher per-patient revenue potential, and stronger partner interest. This focused model can sustain margins and recurring revenues as markets and reimbursement mature.
Strong Recent Revenue ReboundA ~57% revenue rebound in 2025 indicates meaningful commercial traction for the company’s product franchise and improved market uptake. Sustained top-line growth provides leverage to absorb fixed costs, supports reinvestment in launches and trials, and improves prospects for durable cash generation if maintained.
Historical Ability To Reach ProfitabilityThe company demonstrated it can generate strong gross margins and reported positive EBIT and net income in 2023. That historical profitability shows the business model can be economically viable and establishes a realistic pathway to sustainable margins if revenue growth and cost control align going forward.
Bears Say
Weakened Balance SheetNegative equity combined with a large increase in debt materially reduces financial flexibility and raises refinancing risk. Over the medium term this weak capital structure can force costly financing, constrain investment or partnerships, and limit the company’s ability to fund launches or sustain operations without dilution.
Persistent Operating Cash BurnConsistent negative operating and free cash flow (~-35M) means the business is not self-funding and must rely on external capital. Over several months this structural cash burn increases the probability of dilutive financings or asset monetization, and constrains long-term investments in commercialization or R&D.
Highly Volatile ProfitabilityLarge swings from 2023 profitability to deep losses in 2024–2025 create persistent uncertainty around margin sustainability and forecasting. Such volatility undermines partner negotiations, reimbursement discussions, and strategic planning, making durable improvement in cash generation and earnings less predictable.
Santhera Pharmaceuticals Holding News
SANN FAQ
What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?
Santhera Pharmaceuticals Holding lowest stock price was CHF9.38 and its highest was CHF18.84 in the past 12 months.
What is Santhera Pharmaceuticals Holding’s market cap?
Santhera Pharmaceuticals Holding’s market cap is CHF235.17M.
When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?
Santhera Pharmaceuticals Holding’s upcoming earnings report date is Sep 21, 2026 which is in 103 days.
How were Santhera Pharmaceuticals Holding’s earnings last quarter?
Santhera Pharmaceuticals Holding released its earnings results on Apr 28, 2026. The company reported -CHF0.43 earnings per share for the quarter, the consensus estimate of -CHF0.43 by CHF0.
Is Santhera Pharmaceuticals Holding overvalued?
According to Wall Street analysts Santhera Pharmaceuticals Holding’s price is currently Undervalued.
Does Santhera Pharmaceuticals Holding pay dividends?
Santhera Pharmaceuticals Holding does not currently pay dividends.
What is Santhera Pharmaceuticals Holding’s EPS estimate?
Santhera Pharmaceuticals Holding’s EPS estimate is -0.09.
How many shares outstanding does Santhera Pharmaceuticals Holding have?
Santhera Pharmaceuticals Holding has 15,456,525 shares outstanding.
What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?
Santhera Pharmaceuticals Holding reported an EPS of -CHF0.43 in its last earnings report, expectations of -CHF0.43. Following the earnings report the stock price went up 0.98%.
Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?
Currently, no hedge funds are holding shares in CH:SANN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santhera Pharmaceuticals Holding
Santhera Pharmaceuticals Holding AG is a specialized biopharmaceutical firm dedicated to advancing and distributing therapeutic solutions for rare neurological and respiratory conditions characterized by significant patient need across the globe, including the European Union. A cornerstone of its development efforts is vamorolone, currently undergoing clinical trials as a potential treatment for Duchenne muscular dystrophy (DMD). The company's clinical pipeline is further enriched by lonodelestat (also known as POL6014), aimed at addressing cystic fibrosis and various other neutrophilic pulmonary ailments, alongside omigapil, which targets congenital muscular dystrophies. Beyond its pipeline, Santhera also licenses the distribution rights for its approved product, Raxone (idebenone), for the management of Leber's hereditary optic neuropathy, in regions excluding North America and France. Established in 2004, Santhera Pharmaceuticals Holding AG maintains its corporate headquarters in Pratteln, Switzerland.
SANN Company Deck
SANN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with significant market adoption of AGAMREE in Europe and the U.S., strong commercial rollout in China, and increased revenue guidance. However, challenges such as a considerable operating loss and the need for additional financing were also highlighted.View all CH:SANN earnings summariesSANN Stock 12 Month Forecast
Average Price Target
CHF30.00
▲(70.26% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Xlife Sciences Ltd.
―
Options Prices
Currently, No data available
---